The Pharma Top 20s (for PharmExec)
Next >
Top 25 US Products by Sales: Lipitor clung on to the top spot but increasingly feels the impact of generic competition.
Top 20 Global Products: Biologics are increasing apace among the top product offerings, accounting for eight of the 20 biggest selling drugs.
Top 20 Global Therapeutic Classes: The surge in antidiabetics clearly reflects the consequences of lifestyle changes that are edging around the world.
Top 25 Corporations by US Sales: Pfizer holds on at home despite falling Lipitor sales, but the loss of the Lipitor patent at the end of 2011 will make this lead increasingly tenuous.
Top 25 Corporations by US Prescriptions: Increased prescribing of generics saw Watson, Amneal and Lupin Laboratories surge ahead in 2011.
Major patent expiries in 2012.
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
